Compass Pathways completes FDA drug application for psilocybin depression treatment
CMPS•Compass Pathways completed its COMP360 psilocybin new drug application to the U.S. FDA for treatment-resistant depression. The company expects a launch in the first half of 2027, subject to FDA approval.
1. Application completed
Compass Pathways said it completed its COMP360 psilocybin new drug application to the U.S. FDA for treatment-resistant depression. It expects to launch COMP360 in the first half of 2027, subject to FDA approval.
